Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450

• Published in: Drug metabolism and disposition Vol. 48; no. 10; pp. 1008 - 1017
• Main Authors: Bansal, Sumit, Maharao, Neha, Paine, Mary F., Unadkat, Jashvant D.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.2020; The American Society for Pharmacology and Experimental Therapeutics
• Subjects: Administration, Oral; Adult; Cannabidiol - administration & dosage; Cannabidiol - pharmacokinetics; Cytochrome P-450 Enzyme Inhibitors - administration & dosage; Cytochrome P-450 Enzyme Inhibitors - pharmacokinetics; Cytochrome P-450 Enzyme System - metabolism; Dronabinol - administration & dosage; Dronabinol - pharmacokinetics; Drug Evaluation, Preclinical; Drug Interactions; Humans; Inhibitory Concentration 50; Microsomes, Liver; Special Section on Natural Products: Experimental Approaches to Elucidate Disposition Mechanisms and Predict Pharmacokinetic Drug Interactions; G6P; FDA; CBD; HLM; PBPK; FaSSIF; THC; 11-OH-THC; AUC; BSA; LC-MS/MS; COOH-THC; FeSSIF; UPLC; TDI; CYP; AUCR

Cannabis is used for both recreational and medicinal purposes. The most abundant constituents are the cannabinoids - cannabidiol (CBD, nonpsychoactive) and (−)-trans-Δ9-tetrahydrocannabinol (THC, psychoactive). Both have been reported to reversibly inhibit or inactivate cytochrome P450 (CYPs) enzyme...